Weight loss

Monoclonal antibodies
#iBio #Monoclonal antibodies #Phase I trial #Weight loss

iBio initiates Phase I trial for weight loss antibody

iBio has received approval to initiate a first-in-human clinical trial for its long-acting monoclonal antibody IBIO-600 in Australia.  The Phase I study is a randomised, double-blind, placebo-controlled, single ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight and obese adult… Read More

#News

Pills
#Eli Lilly #FDA #GLP-1 #Obesity #Weight loss

FDA approves Lilly’s GLP-1 pill for weight loss

The US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.   "People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water… Read More

#News #Regulatory #Trending News

#ABPI #Clinical trials #GLP-1 #Immune response #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Weight loss

DDW Highlights: 31 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a study found obesity could be treated in other ways than through drugs… Read More

#Podcasts

#ABPI #Clinical trials #Dementia #GLP-1 #Immune response #Neuroscience #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Tregs #Weight loss

This week in Drug Discovery (23 – 27 March) 

News round-up for 23 – 27 March by Bruno Quinney, Content Team at DDW.  This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer has been a central theme in cancer research.   The top stories:    Obesity… Read More

#News

#GLP-1 #Obesity #Weight loss

Obesity could be treated without suppressing appetite 

Obesity could be treated in other ways than using drugs suppressing appetite, a study reveals.  Researchers identified how brown fat cells, which are linked to weight loss, communicate to expand nerve and blood vessel networks, boosting heat generation. The findings, published in Nature Communications, hint at new ways… Read More

#News

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News

#Biomarkers #Genetics #GLP-1 #Weight loss

Genetic markers could predict GLP-1 efficacy, data shows 

Genetic biomarkers could predict GLP-1 efficacy response, results show.  Human omics company Ovation.io and precision medicine company PrecisionLife have released findings from the first phase of their collaboration, showing biomarkers can predict the efficacy, safety and tolerability of GLP-1 therapies.  Using Ovation’s longitudinal clinical and… Read More

#News

Woman standing on scales
#Biopharmaceutical #Clinical trial #GLP-1 #Weight loss

Verdiva Bio completes enrolment for oral GLP-1 trial 

Biopharmaceutical company Verdiva Bio has completed its participant enrolment for the Phase IIb study of its once-weekly oral GLP-1.  VRB-101 is a once-weekly oral, cAMP-biased, GLP-1 peptide analogue candidate for body weight reduction in people with overweight or obesity.  The Phase IIb EVOLVE-2 trial is randomised, double-blind… Read More

#News

Scales showing a comparison between Mounjaro and Ozempic
#GLP-1 #Novo Nordisk #Obesity #Weight loss

Head-to-head obesity trial disappointment for Novo Nordisk 

Novo Nordisk has seen a significant fall in its stock value following disappointing trial results for its obesity treatment CagriSema, which is a fixed dose combination of cagrilintide 2.4mg and semaglutide 2.4mg.  Although CagriSema demonstrated 23% weight loss in the open-label head-to-head Phase III REDEFINE 4 trial,… Read More

#News #Trending News

Map of China
#AstraZeneca #China #Investment #Obesity #Weight loss

AZ expands China operations, agrees obesity deal with CSPC

AstraZeneca has agreed a new strategic collaboration agreement with China’s CSPC Pharmaceuticals to develop multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.   Under this agreement, the companies will initially progress four programmes, which utilise CSPC's AI-driven peptide drug discovery platform and its LiquidGel once-monthly dosing platform… Read More

#Business & Investment #News #Trending News

Overweight man clutching his knee
#Arthritis #Eli Lilly #Monoclonal antibodies #Obesity #Phase III trial #Weight loss

Combination therapy moves the needle in arthritis and obesity

Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together have been shown to deliver superior efficacy in first-of-its-kind Phase IIIb trial for adults with active psoriatic arthritis (PsA) and obesity or who are overweight.  At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all… Read More

#News #Trending News

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

DDW Highlights: 13 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a new report found breast cancer was the world’s most studied disease… Read More

#Podcasts

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

This week in Drug Discovery (5 – 9 January) 

News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW.  This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across… Read More

#News

Weight loss concept
#GLP-1 #Metabolic diseases #MetaVia #Obesity #Phase I trial #Weight loss

Statistically significant PhI results for GLP-1/glucagon dual agonist

MetaVia has announced positive statistically significant results from the eight-week, non-titrated 48mg, multiple ascending dose (MAD) cohort of its Phase I clinical trial of DA-1726.  DA-1726 is a novel, dual oxyntomodulin (OXM) analogue agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for… Read More

#News

#GLP-1 #Ozempic #UCL #Weight loss

1.6 million UK patients used weight loss drugs in past year 

An estimated 1.6 million adults in England, Wales and Scotland used weight loss drugs in the past year, new findings suggest.  The study, led by researchers at University College London, showed 1.6 million adults used drugs including Wegovy and Mounjaro to help lose weight between early 2024 and early 2025. Read More

#News